Tatiana Raskovalova

Multicenter Flow Cytometry For Acute Myeloid Leukemia Measurable Residual Disease With LAIP/DfN And CD34+CD38- Leukemic Stem Cell-Enriched Populations

Adriana Pleșa, Florent Dumézy, Stéphanie Mathis, Isabelle Arnoux et autres

fraction. A backbone of CD34/CD38/CD45/CD117 was used, completed by lineage markers for the first tube, LSC-associated markers for the second tube, and monocytic and differentiation markers for the third tube. This panel can be used in 8-, 10-, and 12-color formats and …

fr, us, be (code pays fourni par la source)

Flow cytometric lyophilised reagent tube assay for peripheral blood neutrophil myeloperoxidase expression to rule out myelodysplastic neoplasms at a university hospital: a diagnostic accuracy study

Charlotte Planta, Laura Scheffen, Marie‐Christine Jacob, Gautier Szymanski et autres

OBJECTIVES: Although flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression can accurately rule out myelodysplastic neoplasms (MDS), it lacks reliability and efficiency due to the practical limitations of laboratory-developed liquid reagent-based assays. This study aimed to quantify the agreement and comparative …

fr, gb (code pays fourni par la source)

Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Adriana Pleșa, Stéphanie Mathis, Florent Dumézy, Anne‐Catherine Lhoumeau et autres

Introduction MRD monitoring is recommended for treatment response evaluation in clinical AML trials (ELN-2022 guidelines: Heuser et al, PMID 34724563). Besides molecular biology methods, multiparametric flow cytometry represents the most reliable approach. In this study, we evaluated the impact of flow MRD …

fr (code pays fourni par la source)

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

Sylvain Garciaz, Pierre‐Yves Dumas, Sarah Bertoli, David Andrew Sallman et autres

Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed …

fr, us (code pays fourni par la source)

Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms (MPO-MDS-Valid): protocol for a multicentre diagnostic accuracy study

Charlotte Planta, Caroline Bret, Delphine Manzoni, Anne‐Catherine Lhoumeau et autres

INTRODUCTION: Many patients referred for suspicion of myelodysplastic neoplasm (MDS) are subjected to unnecessary discomfort from bone marrow aspiration, due to the low disease prevalence in this population. Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression could rule out MDS with …

fr (code pays fourni par la source)

Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression in myelodysplastic neoplasms

Tatiana Raskovalova, Marie‐Christine Jacob, Sophie Park

fr (code pays fourni par la source)

The onset of late severe lung impairment in COVID-19 is associated with high inflammation markers at admission and metabolic syndrome markers

Olivier Épaulard, Audrey Le Gouëllec, Marion Le Maréchal, Benjamin Némoz et autres

Abstract Background COVID-19 severity is mainly related to lung impairment. However, preexisting patient characteristics and biomarkers at admission associated with this event are not precisely known. Methods We report 205 patients admitted for a proven COVID-19 in our institution between March 7 …

fr (code pays fourni par la source)

Comparative diagnostic accuracy between simplified and original flow cytometric gating strategies for peripheral blood neutrophil myeloperoxidase expression in ruling out myelodysplastic syndromes

Tatiana Raskovalova, Laura Scheffen, Marie‐Christine Jacob, Claire Vettier et autres

BACKGROUND: Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression is accurate in ruling out myelodyplastic syndromes (MDS) but might not be suitable for implementation in busy clinical laboratories. We aimed to simplify the original gating strategy and examine its accuracy. METHODS: …

fr (code pays fourni par la source)

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Adriana Pleșa, Florent Dumézy, Stéphanie Mathis, Anne‐Catherine Lhoumeau et autres

Introduction: MRD follow-up is now mandatory for treatment response evaluation in AML clinical trials (ELN 2017 and 2021 guidelines: Heuser et al,Blood doi:10.1182/blood.2021013626.). Beside to molecular biology methods, multiparameter flow cytometry assay represents the most reliable approach. The aim of this study …

fr (code pays fourni par la source)

Flow cytometry lyophilised-reagent tube for quantifying peripheral blood neutrophil myeloperoxidase expression in myelodysplastic syndromes (MPO-MDS-Develop): protocol for a diagnostic accuracy study

Tatiana Raskovalova, Laura Scheffen, Marie‐Christine Jacob, Simon Chevalier et autres

INTRODUCTION: Suspicion of myelodysplastic syndromes (MDS) is the most common reason for bone marrow aspirate in elderly patients. Peripheral blood neutrophil myeloperoxidase expression quantified by flow cytometric analysis might rule out MDS for up to 35% of patients referred for suspected disease, …

fr (code pays fourni par la source)

Fine Analysis of Lymphocyte Subpopulations in SARS-CoV-2 Infected Patients: Differential Profiling of Patients With Severe Outcome

Giovanna Clavarino, Corentin Leroy, Olivier Épaulard, Tatiana Raskovalova et autres

COVID-19 is caused by the human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in widespread morbidity and mortality. CD4 + T cells, CD8 + T cells and neutralizing antibodies all contribute to control SARS-CoV-2 infection. However, heterogeneity is …

fr (code pays fourni par la source)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL

Antonin Bouroumeau, Lucile Bussot, Sieme Hamaidia, Andrea Cecilia Garcia-Sandoval et autres

R-CHOP immuno-chemotherapy significantly improved clinical management of diffuse large B-cell lymphoma (DLBCL). However, 30-40% of DLBCL patients still present a refractory disease or relapse. Most of the prognostic markers identified to date fail to accurately stratify high-risk DLBCL patients. We have previously …

fr, ch (code pays fourni par la source)